JPY 2065.0
(0.05%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 716 Million JPY | 25.83% |
2022 | 569 Million JPY | 90.3% |
2021 | 299 Million JPY | 34.08% |
2020 | 223 Million JPY | -50.88% |
2019 | 454 Million JPY | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | 316 Million JPY | 237.39% |
2023 Q3 | 325 Million JPY | 30.0% |
2023 Q2 | 250 Million JPY | -32.61% |
2023 Q4 | -230 Million JPY | -170.77% |
2023 FY | 716 Million JPY | 25.83% |
2023 Q1 | 371 Million JPY | 1755.0% |
2022 Q3 | -1 Million JPY | -100.74% |
2022 FY | 569 Million JPY | 90.3% |
2022 Q4 | 20 Million JPY | 2100.0% |
2022 Q2 | 135 Million JPY | 0.0% |
2021 FY | 299 Million JPY | 34.08% |
2020 FY | 223 Million JPY | -50.88% |
2019 FY | 454 Million JPY | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Pharma Foods International Co., Ltd. | 5.11 Billion JPY | 85.996% |
Takeda Pharmaceutical Company Limited | 214.07 Billion JPY | 99.666% |
Sumitomo Pharma Co., Ltd. | -354.19 Billion JPY | 100.202% |
Shionogi & Co., Ltd. | 171.46 Billion JPY | 99.582% |
Wakamoto Pharmaceutical Co.,Ltd. | -195.51 Million JPY | 466.22% |
Nippon Shinyaku Co., Ltd. | 31.38 Billion JPY | 97.719% |
Kaken Pharmaceutical Co., Ltd. | 9.51 Billion JPY | 92.473% |
Eisai Co., Ltd. | 53.4 Billion JPY | 98.659% |
Hisamitsu Pharmaceutical Co., Inc. | 13.16 Billion JPY | 94.562% |
Mochida Pharmaceutical Co., Ltd. | 5.8 Billion JPY | 87.662% |
Fuso Pharmaceutical Industries,Ltd. | 1.96 Billion JPY | 63.544% |
Nippon Chemiphar Co., Ltd. | -494 Million JPY | 244.939% |
Tsumura & Co. | 20.01 Billion JPY | 96.423% |
Kissei Pharmaceutical Co., Ltd. | 4.01 Billion JPY | 82.176% |
Torii Pharmaceutical Co., Ltd. | 5.03 Billion JPY | 85.782% |
Towa Pharmaceutical Co., Ltd. | 17.64 Billion JPY | 95.943% |
Fuji Pharma Co., Ltd. | 3.85 Billion JPY | 81.441% |
Zeria Pharmaceutical Co., Ltd. | 9.71 Billion JPY | 92.631% |
KYORIN Holdings, Inc. | 6.01 Billion JPY | 88.092% |
Taiko Pharmaceutical Co.,Ltd. | -3.07 Billion JPY | 123.254% |
Daito Pharmaceutical Co.,Ltd. | 3.89 Billion JPY | 81.613% |
SymBio Pharmaceuticals Limited | -811.66 Million JPY | 188.213% |
MedRx Co., Ltd | -933 Million JPY | 176.742% |
Mizuho Medy Co.,Ltd. | 5.15 Billion JPY | 86.102% |
Solasia Pharma K.K. | -1.13 Billion JPY | 162.862% |
Modalis Therapeutics Corporation | -2.37 Billion JPY | 130.211% |
ASKA Pharmaceutical Holdings Co.,Ltd. | 6.5 Billion JPY | 88.985% |
Sawai Group Holdings Co., Ltd. | 18.88 Billion JPY | 96.209% |
Cyfuse Biomedical K.K. | -697.43 Million JPY | 202.662% |
Toho Holdings Co., Ltd. | 19.33 Billion JPY | 96.296% |
Koa Shoji Holdings Co.,Ltd. | 4.38 Billion JPY | 83.662% |